|Articles|September 20, 2021
Building Biotech Series with Tom Jarvie
Author(s)Thermo Fisher Scientific
One of the greatest unexplored spaces of the world is the microbiome, a bustling network of trillions of microorganisms living inside each of us. If we could learn more about them, the advancements we’d make in healthcare and other fields would be incredible. This line of thinking is what spurred Tom Jarvie and Mark Driscoll to found Shoreline Biome, maker of the most complete end-to-end microbiome sample prep kits on the market. Hear their incredible story in this Building Biotechs podcast.
Episodes in this series
Related to this article
Topline phase 3 data show epcoritamab plus R-CHOP reduced the risk of progression or death by 51% in newly diagnosed diffuse large B-cell lymphoma.
Part 2 of the VK2735 maintenance study tests whether daily or weekly oral tablets can hold weight loss first achieved with weekly subcutaneous injections.
CSL and Alentis will co-develop lixudebart, an antibody targeting claudin-1, across 3 rare kidney and liver disease indications.
AL050 aims to treat GBA1-driven Parkinson disease by delivering a GCase enzyme across the blood-brain barrier.
Survodutide advances metabolic disease treatment, while biosimilar capacity expands, FDA delays hemophilia review, and lupus data support next steps.
Litifilimab extended skin responses through 52 weeks in phase 2 AMETHYST data in cutaneous lupus erythematosus, with phase 3 results expected in 2027.
Manufacturing remediation, not efficacy or safety data, is delaying US approval of Novo's h+emophilia A therapy denecimig.
Doubled drug substance capacity at Alvotech's Reykjavik, Iceland, site aims to secure steady US supply of the Humira biosimilar Simlandi.